Mercury Biopharmaceutical Corporation (TPEX:6932)
Taiwan
· Delayed Price · Currency is TWD 11.15
+0.35 (3.24%)
At close: Dec 5, 2025
Mercury Biopharmaceutical Revenue
Mercury Biopharmaceutical had revenue of 246.00K TWD in the twelve months ending June 30, 2025, down -95.72% year-over-year. In the year 2024, Mercury Biopharmaceutical had annual revenue of 4.96M with 380.45% growth.
Revenue (ttm)
246.00K
Revenue Growth
-95.72%
P/S Ratio
18,966.06
Revenue / Employee
n/a
Employees
16
Market Cap
4.67B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caliway Biopharmaceuticals | 34.99M |
| PharmaEssentia | 13.82B |
| Lotus Pharmaceutical | 18.66B |
| Bora Pharmaceuticals Co., LTD. | 21.10B |
| Oneness Biotech | 117.33M |
| Lumosa Therapeutics | 42.59M |
| Center Laboratories | 1.57B |
| Pegavision | 6.90B |